Literature DB >> 12168752

Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?

M Miravitlles1.   

Abstract

The progressive course of chronic obstructive pulmonary disease (COPD) is often aggravated by exacerbations, the majority of them produced by bronchial infection. Frequent exacerbations have been demonstrated to have a negative impact on quality of life and pulmonary function in patients with COPD, particularly in active smokers. Furthermore, acute exacerbations are the most frequent cause of medical visits, hospital admissions and death among patients with chronic lung disease. Evidence indicates that the number of patients with pathogenic bacteria in respiratory secretions and the bronchial bacterial load increase during exacerbations. Furthermore, the local inflammatory response of the host parallels the increase in bacterial load. From these observations, it can be speculated that, for symptoms of acute exacerbation to appear, there must be a minimum bacterial load in the airways, i.e. a threshold above which the inflammatory reaction is severe enough to elicit clinical symptoms of exacerbation. This threshold may vary from patient to patient owing to different modifying factors. Some of these factors may be the recognised risk factors for relapse, such as increasing age, impairment of lung function, comorbid conditions or frequent exacerbations in the past. Relapse rates after ambulatory treatment of acute exacerbation of COPD may be as high as 20-25% of cases. Relapses are associated with significant mordibity and increased costs. A number of unanswered questions remain regarding exacerbations of chronic obstructive pulmonary disease. These include the role of viral infection, the importance of residual bacterial colonisation and the impact of new antibiotics on the treatment of exacerbations.

Entities:  

Mesh:

Year:  2002        PMID: 12168752     DOI: 10.1183/09031936.02.00400302

Source DB:  PubMed          Journal:  Eur Respir J Suppl        ISSN: 0904-1850


  30 in total

Review 1.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

2.  Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency.

Authors:  Daniel J Smith; Paul R Ellis; Alice M Turner
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

3.  Nosocomial outbreak of Corynebacterium striatum infection in patients with chronic obstructive pulmonary disease.

Authors:  Feliu Renom; Margarita Garau; Mateu Rubí; Ferran Ramis; Antònia Galmés; Joan B Soriano
Journal:  J Clin Microbiol       Date:  2007-04-04       Impact factor: 5.948

Review 4.  [Antibiotic therapy for exacerbation].

Authors:  K Dalhoff; H Kothe
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

Review 5.  [Assessment, triage, and follow-up of a patient with: acute CAP COPD].

Authors:  K Faure
Journal:  Med Mal Infect       Date:  2006-11-07       Impact factor: 2.152

6.  Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of life.

Authors:  Marc Miravitlles; Carles Llor; Jesús Molina; Karlos Naberan; Josep M Cots; Fernando Ros
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-02-18

7.  Colour of sputum is a marker for bacterial colonisation in chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Alicia Marín; Eduard Monsó; Sara Vilà; Cristian de la Roza; Ramona Hervás; Cristina Esquinas; Marian García; Laura Millares; Josep Morera; Antoni Torres
Journal:  Respir Res       Date:  2010-05-14

8.  Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Miriam Calle; Francisco Alvarez-Gutierrez; Elena Gobartt; Francisco López; Antonio Martín
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

9.  C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT.

Authors:  Nick A Francis; David Gillespie; Patrick White; Janine Bates; Rachel Lowe; Bernadette Sewell; Rhiannon Phillips; Helen Stanton; Nigel Kirby; Mandy Wootton; Emma Thomas-Jones; Kerenza Hood; Carl Llor; Jochen Cals; Hasse Melbye; Gurudutt Naik; Micaela Gal; Deborah Fitzsimmons; Mohammed Fasihul Alam; Evgenia Riga; Ann Cochrane; Christopher C Butler
Journal:  Health Technol Assess       Date:  2020-03       Impact factor: 4.014

10.  Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care.

Authors:  Carl Llor; Silvia Hernández; Anna Ribas; Carmen Alvarez; Josep Maria Cots; Carolina Bayona; Isabel González; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.